-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-503831-17-00
4
2019-12-23
The treatment of participants with HRRm and/or HRD-positive cancer
-
2023-506184-34-00
5
2019-08-09
Advanced Malignancies
-
2024-514274-46-00
5
2019-06-21
Solid Tumors
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2024-511648-16-00
5
2019-01-04
Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresecta
-
2024-516662-11-00
5
2018-11-23
Ovarian epithelial
cancer
-
2023-506994-36-00
5
2018-10-11
Ulcerative Colitis
-
2023-506861-76-00
5
2018-08-09
Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2023-506399-28-00
5
2017-11-08
Crohn's Disease
-
2023-504951-29-00
5
2017-07-27
Chron's Disease
-
2024-518951-52-00
4
2025-11-12
Worsening Heart Failure
-
2024-512313-41-00
5
2025-05-19
Stable Angina Pectoris
-
2022-502049-91-00
4
2023-09-26
SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
-
2023-507705-34-00
5
2025-08-29
Moderate to Severe Active Ulcerative Colitis
-
2024-518364-12-00
4
2025-05-09
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
2024-516840-24-00
3
2025-03-05
Chronic Kidney disease
-
2024-512505-66-00
10
2025-03-03
HIV-1 Infection
-
2024-511057-22-00
5
2024-12-04
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia